Rady Children's Institute for Genomic Medicine

What Rady Children's Institute for Genomic Medicine does

Rady Children's Institute for Genomic Medicine (RCIGM) is a non-profit research institute founded in 2016 and embedded within Rady Children's Hospital-San Diego. It operates a CLIA-certified and CAP-accredited clinical laboratory delivering rapid Whole Genome Sequencing (rWGS) and ultra-rapid Whole Genome Sequencing (urWGS) for critically ill infants and children in NICU and PICU settings, with diagnostic results typically returned in under three days and as fast as 48 hours for time-sensitive cases. The institute pairs sequencing with AI-augmented variant interpretation, clinical Natural Language Processing to compress the diagnostic odyssey, and a treatment-guidance tool (Genome-to-Treatment, GTRx) covering roughly 500 treatable genetic diseases.

The commercial offering is the Rapid Precision Medicine (RPM) platform, sold to children's hospitals and health systems through a partner-hospital ordering model in which samples are sent to RCIGM's San Diego laboratory. RCIGM has built a clinical evidence base through state-funded pilots — Project Baby Bear (California), Project Baby Deer (Michigan), and Project Baby Manatee (Florida) — that documented diagnosis rates of 39-52%, change-of-management rates of 27-31%, and net per-patient savings of several thousand dollars. These pilots drove Medicaid coverage adoption in at least five states and commercial coverage from Blue Shield of California.

Beyond acute-care diagnostics, RCIGM launched the BeginNGS consortium in June 2022 to scale newborn genomic screening for 1,000+ treatable disorders; the consortium had 22+ founding members by mid-2023 and expanded internationally in 2025 through anchor partnerships with Sidra Medicine (Qatar) and King Faisal Specialist Hospital & Research Centre (Saudi Arabia). Revenue is derived from a combination of clinical laboratory fees reimbursed by Medicaid and commercial insurers, state-funded pilot and demonstration program grants, and philanthropy, with the parent Rady Children's Hospital-San Diego providing institutional infrastructure.

Name

Rady Children's Institute for Genomic Medicine

Legal name

Rady Children's Institute for Genomic Medicine

Website

https://radygenomics.org

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Rady Children's Institute for Genomic Medicine is a non-profit research institute operating a CLIA-certified clinical laboratory that provides rapid and ultra-rapid whole genome sequencing diagnostics to children's hospitals, Medicaid programs, and an international newborn screening consortium focused on critically ill infants.

Ownership category

akta.pro rank

Product category

Pediatric Genomic Medicine Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLAFAMAE

Molecular Diagnostics & Genomics Laboratories

Healthcare & Life Sciences/Healthcare Providers & Systems/Clinical Laboratories

SECONDARYHLAFAMAH

Genetic & Prenatal Testing Laboratories

Healthcare & Life Sciences/Healthcare Providers & Systems/Clinical Laboratories

SECONDARYHLAAALAD

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

SECONDARYHLAHAAAI

Genetic, Cytogenetic & Prenatal Screening IVD

Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

SECONDARYHLAAALAJ

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

SECONDARYHLAGANAA

Genomics & Next-Generation Sequencing (NGS) Services

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

• Pediatric genomic medicine
• Rapid whole genome sequencing
• Rare disease diagnosis
• Newborn genetic screening
• Clinical laboratory services

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Clinical Laboratory Services: RCIGM operates a CLIA-certified and CAP-accredited clinical laboratory providing rapid whole genome sequencing diagnostic services to children's hospitals and healthcare systems. Revenue is generated through test ordering by partner hospitals, with reimbursement from Medicaid programs, commercial insurance, and direct pay arrangements.
2. Research Grants and Collaborations: RCIGM receives research funding from state government programs, federal grants, and pharmaceutical company partnerships for clinical trials and consortium research activities.
3. Insurance and Medicaid Reimbursement: RCIGM's services are covered by Medicaid programs in multiple states (California, Michigan, Florida, Arizona, Tennessee) and commercial insurers including Blue Shield of California. Reimbursement is separate from DRG payments for eligible inpatient cases.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

Rady Children's Institute for Genomic Medicine (RCIGM) operates a CLIA-certified and CAP-accredited clinical laboratory providing rapid Whole Genome Sequencing (rWGS) and ultra-rapid Whole Genome Sequencing (urWGS) diagnostic services to children's hospitals and health systems for critically ill infants and children with suspected rare genetic diseases. The institute also runs the BeginNGS newborn genomic screening consortium and provides clinical interpretation, Genome-to-Treatment (GTRx) decision support, and educational programs to advance pediatric precision medicine.

Product overview

Rady Children's Institute for Genomic Medicine (RCIGM) offers a unified portfolio centered on Rapid Precision Medicine (RPM), combining ultra-rapid and rapid Whole Genome Sequencing (urWGS/rWGS) as the core diagnostic engine with the BeginNGS newborn screening program for population-scale screening, and the Genome-to-Treatment (GTRx) tool that translates diagnoses into actionable treatment guidance. The company provides clinical laboratory services (Clinical Genome Services) to partner hospitals and health systems, supported by public health demonstration programs (Project Baby Bear, Baby Deer, Baby Manatee) that generate evidence for insurance coverage. Educational offerings through the RCIGM Learning Network and RPM Grand Rounds complete the ecosystem. The architecture is platform-based: urWGS/rWGS delivers same- or next-day results for ICU patients while BeginNGS enables prospective newborn screening at scale, with GTRx linking every diagnosis to curated treatment protocols.

Differentiator

Problem solved

Functional benefit

Brands

• BeginNGS: Newborn genomic sequencing consortium and program targeting early detection of genetic disorders
• RPM Rapid Precision Medicine™
• rWGS (Rapid Whole Genome Sequencing)
• urWGS (Ultra-Rapid Whole Genome Sequencing)

Products and services

• Rapid Precision Medicine (RPM)
• Rapid Whole Genome Sequencing (rWGS)
• Ultra-Rapid Whole Genome Sequencing (urWGS)
• BeginNGS Newborn Genomic Sequencing
• Genome-to-Treatment (GTRx)
• Clinical Genome Services

Quantifiable outcome

• 43% of infants received a genetic diagnosis explaining their condition
• +5 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability10 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• King Faisal Specialist Hospital & Research CentrecoreStrategic or Co-development Partner · 10 October 2025King Faisal Specialist Hospital & Research Centre in Riyadh, Saudi Arabia joined the BeginNGS consortium led by RCIGM. The partnership enables sequencing-based newborn screening in the Middle East, supporting early detection and tailored treatments for genetic diseases. KFSHRC has become a regional leader in genomic medicine through its Genomic Medicine Center.
• AstraZeneca AlexioncoreStrategic or Co-development Partner · 10 October 2025Alexion, AstraZeneca's Rare Disease group, is a partner in the BeginNGS consortium, contributing to the goal of preventing or reducing effects of childhood genetic diseases by identifying at-risk infants early through newborn screening.
• Sidra MedicinecoreStrategic or Co-development Partner · 19 August 2025Sidra Medicine in Qatar partnered with BeginNGS to launch genome-based newborn screening research program. The collaboration expands newborn screening capabilities in Qatar to screen for more than one thousand treatable genetic disorders, marking BeginNGS's entry into the Middle East.
• Nicklaus Children's HospitalcoreStrategic or Co-development Partner · 1 August 2023Nicklaus Children's Hospital led Project Baby Manatee in Florida, a pilot initiative assessing the impact of providing rapid whole genome sequencing for critically ill infants. The successful pilot led to Florida Medicaid coverage of rWGS for eligible infants and children.
• AdventHealth for ChildrencoreStrategic or Co-development Partner · 5 October 2020AdventHealth for Children partnered with RCIGM to bring rapid and ultra-rapid whole genome sequencing to Central Florida families. This partnership provides the quickest turnaround of genomic test results available in the country to patients in Central Florida, with preliminary diagnoses typically available in less than three days for medically urgent cases.

Scale indicators6 records

Recent moves3 records

Expansion highlights5 records

Others

• Fabric Genomics: Fabric Genomics provides AI-powered genome interpretation software (GEM AI) used by RCIGM to enhance rare disease diagnosis; a technology/AI partner and adjacent ecosystem player in clinical genomic interpretation rather than a direct testing competitor.
• Illumina: Illumina is the dominant DNA sequencing technology provider and RCIGM's core sequencing infrastructure partner; not a direct competitor but a critical enabling technology provider whose pricing and platform roadmap directly shape RCIGM's cost structure and differentiation potential.

Direct peers

• GeneDx: GeneDx (formerly part of Sema4) is a leading clinical genomics lab specializing in rare disease and pediatric whole genome sequencing; directly comparable to RCIGM in offering rapid WGS for NICU/PICU patients with similar reimbursement dynamics through Medicaid and commercial payers.
• Baylor Genetics: Baylor Genetics is a CLIA-certified clinical genomics laboratory within Baylor College of Medicine offering whole genome and exome sequencing for rare pediatric disease diagnosis; directly comparable in clinical genomic testing services, customer base (children's hospitals), and academic medical center affiliation.
• PerkinElmer Genomics: PerkinElmer Genomics (now Revvity) operates a clinical genomics laboratory offering whole genome sequencing and rare disease diagnostics; comparable to RCIGM in clinical WGS services for pediatric and rare disease indications with multi-state lab operations.
• PreventionGenetics: PreventionGenetics (acquired by Exact Sciences) is a CLIA-certified clinical DNA testing laboratory offering whole genome sequencing and clinical genetic testing; comparable in clinical genomic testing infrastructure and rare disease focus.

Broad incumbents

• Natera: Natera is a commercial genetic testing company known for reproductive and oncology testing but expanding into rare disease and pediatric genetic testing; a broader incumbent with overlapping clinical genomic capabilities and significantly greater commercial scale.
• Tempus Labs: Tempus Labs is an AI-powered precision medicine company offering genomic sequencing and clinical interpretation services across oncology and rare disease; comparable in AI-driven clinical genomic interpretation and sequencing platform, with much broader scope and commercial scale.
• Ambry Genetics: Ambry Genetics (acquired by Konica Minolta) is an established clinical genetic testing laboratory offering exome and genome sequencing for rare disease; comparable in clinical genomic testing services with broader commercial scale and test menu than RCIGM.
• Invitae: Invitae (now part of Labcorp) is a large commercial genetic testing company offering comprehensive clinical genetic testing including rare disease panels and WGS; a broader incumbent in clinical genomics with greater commercial scale and broader test menu than RCIGM's pediatric WGS focus.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/radygenomics
• LinkedInlinkedin.com/company/rady-childrens-institute-for-genomic-medicine

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rady Children's Institute for Genomic Medicine